Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.

Boyce AM, Kelly MH, Brillante BA, Kushner H, Wientroub S, Riminucci M, Bianco P, Robey PG, Collins MT.

J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40. doi: 10.1210/jc.2014-1371. Epub 2014 Jul 17.

2.

Bisphosphonate treatment for children with disabling conditions.

Boyce AM, Tosi LL, Paul SM.

PM R. 2014 May;6(5):427-36. doi: 10.1016/j.pmrj.2013.10.009. Epub 2013 Dec 22. Review.

3.

Bone mineral density in developing children with osteogenesis imperfecta: a longitudinal study with 9 years of follow-up.

Kok DH, Sakkers RJ, Pruijs HE, Joosse P, Castelein RM.

Acta Orthop. 2013 Aug;84(4):431-6. doi: 10.3109/17453674.2013.831321.

4.

Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I.

Iwamoto J, Sato Y, Uzawa M, Matsumoto H.

Ther Clin Risk Manag. 2013;9:1-7. doi: 10.2147/TCRM.S38404. Epub 2012 Dec 28.

5.

Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta.

Wekre LL, Eriksen EF, Falch JA.

Arch Osteoporos. 2011;6:31-8. doi: 10.1007/s11657-011-0054-z. Epub 2011 Apr 14.

6.

Current and emerging treatments for the management of osteogenesis imperfecta.

Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, Doro F, Perlini S, Cavarzere P, Antoniazzi F.

Ther Clin Risk Manag. 2010 Sep 7;6:367-81.

7.

Metaphyseal bands in osteogenesis imperfecta.

Suresh S, Thomas JK.

Indian J Radiol Imaging. 2010 Feb;20(1):42-4. doi: 10.4103/0971-3026.59752.

8.

SAPHO Syndrome Diagnosis and Treatment: Report of Five Cases and Review of the Literature.

Matzaroglou Ch, Velissaris D, Karageorgos A, Marangos M, Panagiotopoulos E, Karanikolas M.

Open Orthop J. 2009 Nov 5;3:100-6. doi: 10.2174/1874325000903010100.

9.

Bisphosphonate treatment in the oim mouse model alters bone modeling during growth.

Rao SH, Evans KD, Oberbauer AM, Martin RB.

J Biomech. 2008 Dec 5;41(16):3371-6. doi: 10.1016/j.jbiomech.2008.09.028. Epub 2008 Nov 20.

10.
11.

Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.

Aström E, Jorulf H, Söderhäll S.

Arch Dis Child. 2007 Apr;92(4):332-8. Epub 2006 Nov 17.

12.

Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis.

Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O'Neill TW, Symmons D.

Arch Dis Child. 2006 Sep;91(9):753-61. Epub 2006 May 11. Review.

13.

Bisphosphonate treatment of bone disease.

Shaw NJ, Bishop NJ.

Arch Dis Child. 2005 May;90(5):494-9. Review.

14.

Does the use of a specialised paediatric retrieval service result in the loss of vital stabilisation skills among referring hospital staff?

Ramnarayan P, Britto J, Tanna A, Thomas D, Alexander S, Habibi P.

Arch Dis Child. 2003 Oct;88(10):851-4.

15.
16.

Modeling the benefits of pamidronate in children with osteogenesis imperfecta.

Lindsay R.

J Clin Invest. 2002 Nov;110(9):1239-41. No abstract available.

Supplemental Content

Support Center